OXiGENE is a biopharmaceutical company developing new and improved therapeutics that deliver significant medical benefits to patients with cancer and sight-threatening eye diseases and conditions.

Our primary focus is developing first-in-class and best-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). VDAs are a new and highly differentiated class of anti-vascular drug candidates that have broad potential therapeutic utility in cancer, eye disease and potentially other diseases/conditions. Because VDAs act differently than anti-angiogenic drugs, VDAs are non-competitive and complementary with anti-angiogenic drugs.

OXiGENE currently has three ongoing VDA drug development programs that address cancer and ophthalmology indications. As described in scientific publications and presentations, our VDA product candidates have demonstrated significant potential in human clinical studies to date in cancer and eye disease.